Loading…
MDxHealth SA is projected to rise to $0.4867 by 2027, a +2% move from its current price of $0.476. MDXH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.4542 | $0.4761 | $0.4991 | +0.03% |
| Jul 15 | $0.4455 | $0.4763 | $0.5091 | +0.06% |
| Jul 16 | $0.439 | $0.4764 | $0.517 | +0.08% |
| Jul 17 | $0.4336 | $0.4765 | $0.5237 | +0.11% |
| Jul 18 | $0.4289 | $0.4767 | $0.5297 | +0.14% |
| Jul 19 | $0.4248 | $0.4768 | $0.5352 | +0.17% |
| Jul 20 | $0.421 | $0.4769 | $0.5403 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.421 | $0.4769 | $0.5403 | +0.20% |
| Week 2 | $0.4005 | $0.4779 | $0.5701 | +0.39% |
| Week 3 | $0.3857 | $0.4788 | $0.5944 | +0.59% |
| Week 4 | $0.3738 | $0.4797 | $0.6158 | +0.79% |
| Week 5 | $0.3636 | $0.4807 | $0.6355 | +0.99% |
| Week 6 | $0.3547 | $0.4816 | $0.6539 | +1.18% |
| Week 7 | $0.3468 | $0.4826 | $0.6714 | +1.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MDxHealth SA is a commercial-stage precision diagnostics company that provides urologic solutions in the United States, Europe, and internationally. Its testing solutions include Confirm mdx for prostate cancer tissue testing that validates an epigenetic test guiding the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers Genomic Prostate Score (GPS), which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
The company sells its products through a urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. It has a collaboration surrounding the initiation of Genomic Prostate Score testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA is a healthcare stock with a current price of $0.4687 and a market capitalization of $24.07M. It is ranked 4853 by market cap. The near-term outlook follows a defined forecast path that places the stock in a low-price range relative to recent highs, with a 2026 average price of $0.4687 and a 30-day range of $0.3363 to $0.6533.
The forecast suggests a gradual, year-by-year evolution rather than a sudden surge in the near term.
A major floor 61.1% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 59.7% above — a clean break opens room to run.
A major ceiling 618.5% above — clearing it would confirm fresh momentum.
Key MDXH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MDXH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4826 | Sell | $0.4802 | Sell |
| MA 10 | $0.4635 | Buy | $0.4815 | Sell |
| MA 20 | $0.4949 | Sell | $0.5354 | Sell |
| MA 50 | $0.9142 | Sell | $0.9471 | Sell |
| MA 100 | $1.87 | Sell | $1.60 | Sell |
| MA 200 | $2.87 | Sell | $2.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.53 | Neutral |
| Stoch RSI (14) | 91.34 | Sell |
| CCI (20) | -32.23 | Neutral |
| Williams %R (14) | -33.91 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -7.57 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 66.09 | Neutral |
| TRIX (15) | -2.87 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 54.64 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 0.49 | Sell |
| ADX (14) | 49.87 | Sell |
| ATR (14) | 0.03 | Info |
Key near-term technical indicators show a neutral posture. The RSI (14) sits at 30, with price action hovering around the $0.40 support and the $0.80 resistance level. The 30-day range is $0.3363 to $0.6533, and the stock’s moving averages place SMA50 at $1.01 and SMA200 at $2.92.
Annualized volatility is high, at 100%, reflecting substantial intra-year swings around a low price level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.40 | $0.476 | $0.5657 | 0% | Neutral | |
| $0.3613 | $0.4867 | $0.7065 | +2% | Neutral | |
| $0.3846 | $0.5459 | $0.8397 | +15% | Neutral | |
| $0.4459 | $0.6617 | $1.06 | +39% | Bullish | |
| $0.4038 | $0.6236 | $1.04 | +31% | Bullish | |
| $0.329 | $0.5273 | $0.9082 | +11% | Neutral | |
| $0.3568 | $0.5923 | $1.05 | +24% | Bullish | |
| $0.3201 | $0.5496 | $0.9989 | +15% | Neutral | |
| $0.3274 | $0.5806 | $1.08 | +22% | Bullish | |
| $0.4304 | $0.788 | $1.50 | +66% | Bullish | |
| $0.3629 | $0.7726 | $1.60 | +62% | Bullish | |
| $0.7168 | $1.59 | $3.66 | +235% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.40 | $0.476 | $0.5633 | +0.00% |
| August 2026 | $0.3908 | $0.4704 | $0.5879 | -1.17% |
| September 2026 | $0.4007 | $0.4883 | $0.6216 | +3.80% |
| October 2026 | $0.3742 | $0.4609 | $0.5959 | -5.62% |
| November 2026 | $0.3413 | $0.4243 | $0.5557 | -7.94% |
| December 2026 | $0.3404 | $0.4268 | $0.5657 | +0.59% |
Click any year to see its month-by-month MDXH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MDXH is projected to trade between $0.40 and $0.5657, averaging $0.476 — a potential gain of 0% from today's $0.476. Price action looks broadly range-bound.
MDxHealth SA's 2027 outlook centres on $0.4867, within a $0.3613 to $0.7065 range. That is up +2% on the projected 2026 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, MDXH could reach as high as $0.8397, with a base case around $0.5459 and support toward $0.3846 — roughly +15% from $0.476. Price action looks broadly range-bound.
Expect MDXH to range from $0.4459 to $1.06 through 2029. The $0.6617 average target implies a +39% move from current prices. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MDXH price prediction for 2030 points to an average of $0.6236 (low $0.4038, high $1.04) — a potential gain of +31% on today's $0.476. Momentum favours further upside here.
In 2031, MDXH is projected to trade between $0.329 and $0.9082, averaging $0.5273 — a potential gain of +11% from today's $0.476. That is -15% versus the projected 2030 average. A consolidation phase looks the most probable path here.
MDxHealth SA's 2032 outlook centres on $0.5923, within a $0.3568 to $1.05 range. That is up +12% on the projected 2031 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2033, MDXH could reach as high as $0.9989, with a base case around $0.5496 and support toward $0.3201 — roughly +15% from $0.476. A consolidation phase looks the most probable path here.
Expect MDXH to range from $0.3274 to $1.08 through 2034. The $0.5806 average target implies a +22% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The MDXH price prediction for 2035 points to an average of $0.788 (low $0.4304, high $1.50) — a potential gain of +66% on today's $0.476. Buyers look set to stay in control over this stretch.
In 2040, MDXH is projected to trade between $0.3629 and $1.60, averaging $0.7726 — a potential gain of +62% from today's $0.476. That is -2% versus the projected 2035 average. Momentum favours further upside here.
MDxHealth SA's 2050 outlook centres on $1.59, within a $0.7168 to $3.66 range. That is up +106% on the projected 2040 average. That marks a +235% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MDXH today (≈ 2,100.840336 MDXH) could be worth
$3,346.59
+$2,346.59 (+235%) by 2050 · US Dollar
Based on the average projected MDXH price of $1.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MDXHwould be worth at today's price.
$1,000 invested in MDXH on Jul 10, 2025 (≈ 458.715582 MDXH) would be worth
$218.35
-$781.65 (-78.2%) today · 0.22× · US Dollar
Based on a MDXH entry price of $2.18 vs. today's $0.476.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.477 | $997.9 | -0.2% |
| 1 month ago | $0.549 | $867.03 | -13.3% |
| 3 months ago | $2.04 | $233.33 | -76.7% |
| 6 months ago | $3.43 | $138.78 | -86.1% |
| 1 year ago | $2.18 | $218.35 | -78.2% |
| All time (4.7y) ago | $12 | $39.67 | -96.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MDXH forecast.
Our base-case forecast reaches $0.95 around 2050.
Implied market cap at $0.95: $48.8M
The multi-year forecast paints a variable but ultimately bullish longer-term path. In 2029 the average price is $0.6642 with a maximum of $1.09 and a minimum of $0.4386, delivering a 41.7% ROI and a bullish tilt. By 2030 the average price is $0.6167 with a max of $1.05 and a min of $0.3898, delivering a 31.6% ROI and a bullish sentiment.
The forecast extends through 2035 (avg $0.7944, max $1.55, ROI 69.5%, bullish) and 2040 (avg $0.7603, max $1.62, ROI 62.2%, bullish), with 2050 showing a strong long-run path (avg $1.59, max $3.65, ROI 238.5%, bullish). Across several years the sentiment is bullish, interspersed with neutral periods, and the scope of potential upside grows substantially by 2050. These figures are estimates and not guarantees; they illustrate potential trajectories based on the provided forecast.
Tap a question to reveal the answer.
Avg price $0.6167; min $0.3898; max $1.05; ROI 31.6%; sentiment BULLISH.
Forecasts show positive ROI in multiple years (e.g., 2029 ROI 41.7%, 2035 69.5%, 2050 238.5%), but some years are neutral or have modest gains and outcomes are not guaranteed. Always consider that these are estimates.
Yes. The forecast max includes $1.09 in 2029 and $1.05 in 2030, with a longer-term max of $3.65 in 2050.
RSI(14) is 30, with SMA50 at $1.01 and SMA200 at $2.92. The 30-day price range is $0.3363 to $0.6533, with support at $0.40 and resistance at $0.80.
Current price is $0.4687 and market cap is $24.07M; the stock ranks 4853.
MDxHealth SA Community Discussion
0Share your MDxHealth SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.